非奈利酮、钠-葡萄糖共转运蛋白-2抑制剂及两者联合应用对心肾保护作用的研究进展
Advances in the cardiorenal protective effects of finerenone,sodium-glucose cotransporter-2 inhibitor and their combination
周明双 1郑绍莹 2张雯 2李雪 2张芹 2赵雅静2
作者信息
- 1. 云南省阜外心血管病医院高血压病区(昆明,650102);西藏自治区人民政府驻成都办事处医院心内科
- 2. 云南省阜外心血管病医院高血压病区(昆明,650102)
- 折叠
摘要
非奈利酮是一种新型非甾体醛固酮受体拮抗剂,其心肾保护作用已得到证实.钠-葡萄糖共转运蛋白-2抑制剂是一类新型降糖药.近期研究表明,其具有独立于降糖的心血管及肾脏保护作用.两药联合应用是否在单药基础上进一步增加心肾获益已成为最新研究热点之一.本文综述了两药单一治疗和联合治疗对心肾保护作用的研究进展,旨在为合理用药及开展进一步的研究提供参考.
Abstract
Finerenone is a novel nonsteroidal aldosterone receptor antagonist with proven cardiorenal protec-tive effects.Sodium-glucose cotransporter-2 inhibitors(SGLT2i)are a new class of hypoglycemic agents,and re-cent studies have shown that they have cardiovascular and renal protective effects independent of glucose.Whether the combination of the two drugs can further increase the cardiac and renal benefits on the basis of monotherapy has become one of the hot spots of the latest research.This article summarizes the progress of cardiorenal protec-tive effects of monotherapy and combination therapy of the two drugs,aiming to provide reference for the rational use of drugs and further research.
关键词
非奈利酮/钠-葡萄糖共转运蛋白-2抑制剂/联合治疗/心肾保护作用Key words
finerenone/sodium-glucose cotransporter-2 inhibitor/combination therapy/cardiorenal protec-tive effects引用本文复制引用
基金项目
云南省心血管病临床医学中心项目(FZX2019-06-01)
云南省心血管系统疾病临床医学研究中心项目(202103AC100004)
云南省阜外心血管病医院人才托举计划学科发展计划(2024RCTJ-XK002)
云南省阜外心血管病医院人才托举计划学科发展计划(2024RCTJ-XK003)
出版年
2024
NETL
NSTL
万方数据